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Summary Cisplatin-based combination chemotherapy is frequently used to treat patients with carcinoma of unknown primary site (CUPS).
Response rates in the literature range from 12% to 26% and median survival from 5 to 7 months. The goal of this study was to evaluate the
combination of carboplatin and prolonged oral etoposide in patients with CUPS, with the hope of minimizing toxicity but improving efficacy and
convenience. Treatment consisted of carboplatin, 300 mg m-2 on day 1, and oral etoposide 50 mg on days 1-20, every 4 weeks for up to nine
cycles. A total of 33 patients were treated and all were evaluable for toxicity. Non-haematological toxicity was mild to moderate, with the
exception of one case of grade 4 stomatitis. Grade 4 leucopenia was observed in eight (24%) patients and sepsis in four (12%), with two and
possibly three treatment-related deaths. For the 26 patients evaluable for response, the response rate was 23% with responses lasting a
median of 11 months (range 7-13 months), with one patient still responding at 12 months. An additional nine patients (35%) had stable
disease. Median survival for all patients was 5.6 months (range 2 weeks to 33 months). The combination of carboplatin with prolonged oral
etoposide has moderate activity similar to that of other platinum-based regimens and is a well tolerated, convenient, outpatient regimen.
Dosing according to estimated creatinine clearance to achieve a carboplatin AUC of 6.0 mg ml-' min might have decreased the incidence of
severe myelotoxicity without compromising the regimen's efficacy.
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Cancer of unknown primary site (CUPS) makes up 5-10% of all
malignancies (Greco and Hainsworth, 1992). There is a general
consensus in the literature that a limited diagnostic evaluation to
identify the few patients with treatable malignancies is the most
cost-effective approach (Levine et al, 1985; Abbruzzese et al,
1995). Several subgroups ofpatients with CUPS have been identi-
fied for whom specific and effective therapy is available. These
are patients with squamous carcinoma in cervical or inguinal
nodes; women with adenocarcinoma in axillary lymph nodes, or
peritoneal carcinomatosis; and patients with neuroendocrine
tumours, or poorly differentiated carcinomas involving mid-line
structures (Greco and Hainsworth, 1992; Hainsworth and Greco,
1993; Daugaard, 1994). The majority of patients with CUPS do
not fit into any ofthese subgroups, and systemic chemotherapy has
frequently been given to them in an attempt to control symptoms
and possibly prolong survival, but the optimal regimen is
unknown. Avoidance of significant toxicity is particularly desir-
able because of the generally poor prognosis of these patients
(Sporn and Greenberg, 1993).
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Platinum-based regimens, similar to those used for germ cell
tumours, such as cisplatin, vinblastine and bleomycin (PVB) have
produced complete responses in 20-30% of selected patients with
poorly differentiated carcinoma or poorly differentiated adenocar-
cinoma (Greco and Hainsworth, 1989, 1992). Etoposide is active
in a wide variety of neoplasms and shows clinical synergism with
cisplatin (Evans et al, 1984). For patients with CUPS, the combi-
nation of cisplatin and etoposide was equivalent to or superior to
PVB (Hainsworth et al, 1991). There is evidence that prolonged
oral etoposide may be more active than the intravenous drug.
Einhorn et al (1990) obtained a 23% response rate with oral etopo-
side 50 mg m-2 for 3 out of 4 weeks in small-cell lung cancer
patients who were refractory to conventional intravenous etopo-
side and cisplatin therapy. Miller described very similar results in
refractory germ cell tumours (Miller et al, 1990). The broad spec-
trum of activity of oral etoposide was noted by Hainsworth et al
(1989), who demonstrated anti-tumour activity with minimal
toxicity in heavily pretreated patients with soft tissue sarcomas,
lymphoma, breast and ovarian cancers. Carboplatin has a very
broad spectrum of activity similar to cisplatin, but is much less
toxic, and has compared favourably when used as a substitute for
cisplatin in a variety ofactive regimens (Bunn, 1990).
Based on the above, we predicted that a combination of
prolonged oral etoposide and carboplatin should have significant
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efficacy in patients with CUPS. Preliminary data showed this to be
a well-tolerated regimen (Evans et al, 1991; Walls et al, 1991). A
fixed low-dose schedule ofetoposide of50 mg perday for 3 weeks
was chosen (Clark et al, 1991; Van der Gaast et al, 1991) to be
given with carboplatin 300 mg m-2 on day 1, every 4 weeks.
Although there were no data to suggest that this schedule ofetopo-
side would be more active than the more commonly used schedule
of 50 mg b.i.d. for 10 or 14 days, the 21-day schedule was chosen
to maximize patient convenience and compliance.
PATIENTS AND METHODS
To be eligible for this study, patients had to have histologically or
cytologically proven malignancy inconsistent with a primary
tumour at the biopsy site and not suggestive of any specific
primary site; history and physical examination, including pelvic
and rectal examination, chest radiograph and abdominal ultra-
sound, which failed to reveal a primary site; measurable or
evaluable disease; no previous chemotherapy; ECOG performance
status of grade 2 or lower; absolute granulocyte count
> 2.0 x 10 1-', platelet count > 100 x 1091-', bilirubin < 35 piM 1-',
and serum creatinine < 150 tM 1-'. Patients were excluded ifthey
had any one of three stool specimens positive for occult blood or
microscopic haematuria, unless a benign cause could be demon-
strated or detailed investigations of the relevant system were
normal. Informed written consent was obtained from all patients.
Pretreatment evaluation included mammography for women, P-
HCG and alpha-fetoprotein for men, and any other investigations
appropriate for the particular case. Patients in subsets with specific
well-defined treatments were excluded. These subsets included
women with adenocarcinoma that involved only axillary lymph
nodes; patients with squamous carcinoma that involved only
cervical or inguinal lymph nodes; and patients with carcinoma that
involved a single potentially resectable tumour site.
Treatment consisted of carboplatin, 300 mg m-2 by intravenous
injection with appropriate antiemetics on day one, and etoposide
50 mg orally daily for 20 days. Cycles were repeated every 4
weeks. Blood counts were checked weekly during treatment. The
protocol initially called for shortening the duration of etoposide
therapy only ifgrade 4 neutropenia was found on the interim blood
counts. After one of the first three patients died during the first
cycle with pancytopenia, the protocol was modified so that etopo-
side was stopped immediately for a granulocyte count <1.0 x 109 1-'
orplatelet count <50 x 109 1-'. For a granulocyte count between 1.1
and 1.5 x 109 1-', orplatelet count between50 and 100 x 1091-, the
etoposide treatment was discontinued after an additional two doses.
The total dose ofboth drugs was reduced by 25% ifgrade 4 myelo-
toxicity occurred on the previous cycle. Therapy was discontinued
for disease progression or patient request. Responding patients
received a minimum of six and maximum of nine courses. Toxicity
was scored after each cycle using ECOG criteria.
Radiographs and scans to assess tumour response were
performed after the second course and every 2 months until
disease progression. Complete response required complete disap-
pearance of all evidence of disease for at least 6 weeks. A partial
response required a 50% or greater decrease in the sum of the
products ofthe two longest perpendicular diameters of all measur-
able lesions, maintained for at least 6 weeks, and no progression of
evaluable lesions or new lesions. Stable disease was defined as
less than 50% regression and less than 25% progression of
measurable disease for at least 6 weeks with no new lesions.
Table 1 Patient characteristics
Eligible number
Median age (range)
Males/females
Performance status (ECOG)
0
1
2
Prior radiotherapy
Histology
Adenocarcinoma
Unspecified
Moderately differentiated
Poorly differentiated
Large cell undifferentiated
Sites of disease
Nodes
Liver
Pleura/peritoneum
Bone
Lung
Skin/soft tissue
Other
Number of disease sites
2
3
.4
33
62 (32-79) years
16/17
7
19
7
3
30
22
4
4
3
15
15
12
9
8
4
9
3
12
12
6
Table 2 Toxicity (n=33)
Worst grade (ECOG) on any cycle
1 2 3 4
Leucopenia 4 13 2 9a
Thrombocytopenia 8 1 3 7
Nausea/vomiting 6 10 2 -
Renal failure 10 1 -
Alopecia 4 3 3
Peripheral neuropathy - - 1
Weakness/fatigue 8 3 1
Stomatitis 6 - - 1
aFour of the nine had fever and/or sepsis, fatal in two cases. One additional
death occurred on day 16, cause unknown.
Progressive disease was defined as a greater than 25% increase in
the sum of the products of two diameters of one or more measur-
able tumours. Patients were considered evaluable for response if
they completed at least two courses of therapy or had disease
progression after the first cycle. All patients who received any
treatment were considered evaluable for toxicity.
The duration of an objective response or progression-free
survival was determined from the first day of treatment until the
time of treatment failure. Overall survival was defined as the
interval from the first day of treatment until the date ofdeath.
After completion of the study, the area under the free carbo-
platin plasma concentration vs time curve (AUC) was calculated
retrospectively for each patient's first cycle using the formula
(Calvert et al, 1989):
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Table 3 Characteristics of responders
Age Sex Performance Histology Sites of disease Number of Response Survival
status courses duration (months) (months)
MS-04 61 F 2 Adenocarcinoma Peripheral nodes; 8 13 2
skin; lung; pleura,
peritoneum
KO-07 51 M 1 Adenocarcinoma Peripheral, 6 11 16
mesenteric and
retroperitoneal
nodes; liver
KO-14 67 M 0 Poorly Supraclavicular and 6 11 11+
differentiated retroperitoneal
adenocarcinoma nodes, mediastinum
MN-02 64 F 0 Poorly Peripheral and 7 12+ 12+
differentiated retroperitoneal
papillary nodes; peritoneum
adenocarcinoma
LO-02 72 M 0 Adenocarcinoma Liver 7 9 16
LY-01 33 F 1 Adenocarcinoma Lung 9 7 24
AUC (mg ml-' min) = carboplatin dose (mg)
(GFR +25)
where GFR is the glomerular filtration rate. The GFR was
estimated by the creatinine clearance (Clcr) as calculated by the
modified formula (Jelliffe, 1973):
Clcr (ml min-') = 98-[0.8 (age - 20)] for males.
Serum creatinine (mg dl-')
For female patients the Clcr is 90% ofthe formula used for male
patients.
RESULTS
Between April 1992 and November 1995, a total of 35 patients at
six hospitals in Ontario, Canada, were enrolled in the study. Two
became ineligible before commencing treatment: one because ofa
rise in serum creatinine and one who decided not to go into the
study after the consent form was signed. The characteristics ofthe
33 treated patients are listed in Table 1. Ninety-one per cent ofthe
patients had adenocarcinoma. Patients typically had extensive
disease, with 18 patients having three or more sites involved. Of
the three patients who had disease in only one site, one had
multiple liver metastases, one multiple bony metastases and one
had several unresectable pleura-based masses.
The median carboplatin AUC for the first treatment cycle was
6.0 mg ml-' min (range 2.8-9.3). The median number oftreatment
cycles was three (range 1-9). Of the total of Ill cycles adminis-
tered, treatment delays of more than 1 week occurred in only five
cycles (5%). Dose reductions ofetoposide were required for only 5
ofthe 28 patients who received more than one cycle. Two patients
required a dose reduction of carboplatin and only one patient
required reduction ofboth drugs. Reasons for treatment discontin-
uation were: disease progression in 16 patients, treatment-related
toxicity or death in five patients, patient's request in three patients
and treatment completion in nine patients.
Toxicity data for the 33 patients are outlined in Table 2. With the
exception of myelosuppression, the treatment was generally well
tolerated with little significant non-haematological toxicity. There
was one case of grade 4 stomatitis and one case ofgrade 3 periph-
eral neuropathy that completely resolved after the treatment was
discontinued. The major serious adverse effect was myelotoxicity.
The median nadir white blood cell count during the first treatment
cycle was 2.8 x 1091- (range 0.2-18.1), with nine patients (27%)
developing nadir white blood cell counts below 1.0 x 1091-'. Three
of these patients developed Gram-negative septicaemia, and a
fourth developed fever without septicaemia, whereas their
neutrophil counts were less than 0.2 x 109 1-'. From the second
cycle onwards, only one patient developed a leucocyte count
below 1.0 x 1091-'. Seven patients (22%) developed platelet counts
below 25 x 109 1-' at some point during the course of treatment.
There were two and possibly three treatment-related deaths. The
first patient, who required emergency surgery on the seventh day
of the first cycle for a perforated bowel and peritonitis secondary
to diverticular disease, died on day 14 ofsepsis with pancytopenia.
A second patient died on day 15 ofGram-negative sepsis and liver
failure with pancytopenia. A third patient, who had a history of
ischaemic cardiomyopathy and cerebrovascular disease, was
treated on day 14 with intravenous fluids because of a 2-day
history ofanorexia and diarrhoea. He died at home 2 days later and
no information about the death could be obtained as no physician
or family member had been present. All three patients had very
extensive metastatic disease at study entry. There was no correla-
tion between toxicity and pretreatment performance status or
previous radiation therapy.
A definite trend towards increasing toxicity with higher carbo-
platin AUC was observed. Only 1 of the 22 patients whose carbo-
platin AUC was less than 6.5 mg ml' min developed sepsis
compared with 3 of the 11 patients whose AUC was greater than
6.5 mg ml-' min (5% vs 27%). Similarly, grade 4 myelotoxicity
occurred in 14% vs 45% of patients whose carboplatin AUC was
below or above 6.5 mg ml' min.
Seven patients were not evaluable for response because they did
not receive a second course of treatment for reasons other than
tumour progression (one toxicity, three deaths, three patient
requests). In the 26 patients evaluable for response, there were six
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partial responses (23%) lasting 7, 9, 11, 12+ and 13 months.
Detailed information on these patients is recorded in Table 3. An
additional nine patients (35%) had stable disease lasting a median
of 6 months (range 3-17 months). One of these patients, whose
pleural biopsy was initially called 'adenocarcinoma', had stable
disease for 6 months and was subsequently found to have multiple
myeloma. No other primary sites of tumour were identified.
A possible trend towards greater efficacy was seen in patients
who had a higher AUC of carboplatin. Of the eight evaluable
patients with an AUC less than 5.5, only one achieved a partial
response (12%) and four (50%) had progressive disease compared
with a 28% response rate and 37% incidence of progressive
disease among the 18 patients with an AUC greater than 5.5. Of
the ten patients whose AUC was in the range of 5.5-6.5, three had
partial responses (30%) and five had progressive disease (50%).
The median survival for all patients was 5.6 months (range
0.5-33 months). The median survival for responding patients and
those with stable disease was 16 months (range 4-33 months).
DISCUSSION
To date, there is no standard polychemotherapy regimen for the
majority of patients with CUPS. The most active regimens
reported in the literature to date can generally be grouped into
doxorubicin based or cisplatin based (Sporn and Greenberg, 1993).
In phase II studies that have included at least 20 patients, the
majority with adenocarcinoma, doxorubicin-based regimens (most
commonly 5-fluorouracil, doxorubicin and mitomycin C) have
produced response rates ranging from 7% to 30% with median
survival ranging from 5 to 11 months. For cisplatin-based regi-
mens, response rates have ranged from 12% to 26% and median
survivals from 5 to 7 months. A possible advantage of the
cisplatin-containing regimens is suggested by a randomized study
in which the response to the combination of doxorubicin, mito-
mycin and cisplatin was 19% compared with 7% for the same
regimen without cisplatin, although, not surprisingly, there was no
difference in the median survival of 5 months (Eagan et al, 1987).
In the 26 patients in this study who were evaluable for response,
a 23% response rate was observed, which is at the higher end of
response rates for cisplatin-containing regimens. We find these
results encouraging for several reasons.
The first reason is that our patient population had extensive
tumour involvement. Indeed, 55% of our patients had three or
more sites of disease and this has been shown in several series to
be predictive of a poor outcome (Daugaard, 1994). As the number
of disease sites is not specified in most of the published reports, a
direct comparison ofpatient groups is impossible.
The second reason is that the dose of carboplatin received by
many ofthe patients in our study was suboptimal. Carboplatin was
given at a dose of 300 mg m-2 rather than according to the now
standard method of dosing recommended by Calvert, based on the
patient's calculated creatinine clearance and a target AUC (Calvert
et al, 1989). This could be one explanation for the discrepancy
between our results and those reported by Merrouche et al (1994),
who achieved a response rate of 36% in 22 patients with CUPS
using cisplatin 100 mg m-2 on day one and intravenous etoposide
100 mg m-2 days 1-3. A study by Gill et al (1991), however,
suggests that there is an upper limit to what might be expected
from increasing the drug doses. In their study a very dose-intense
regimen consisting of cisplatin 100 mg m-' on days 1 and 8 and
etoposide 80 mg m-2 on days 1, 2, 8 and 9 provided only a 19%
response rate and excessive toxicity. Indeed, when we calculated
the carboplatin AUC for the first course of therapy for each of our
patients retrospectively, we found no evidence for increasing effi-
cacy beyond a threshold AUC of 5.5 mg ml-' min, and a signifi-
cant increase in toxicity above an AUC of 6.5. The optimal
carboplatin AUC for this regimen would thus be 6.0 mg ml-' min,
which, coincidentally, was the median AUC achieved by our
patients.
The final reason for encouragement is that, in recent years,
patients most likely to respond to treatment have been identified
(e.g. those with neuroendocrine features or women with peritoneal
carcinomatosis) and are no longer included in clinical trials for
CUPS patients. In addition, more precise diagnostic techniques are
excluding patients with lymphomas and other treatable malignan-
cies who would formerly have been classified as having CUPS.
Thus, a response rate at the higher end of what is reported in the
older literature may be truly significant.
A recently reported study (Hainsworth et al, 1997) should be
mentioned in which 55 patients were treated with the combination
of paclitaxel 200 mg m-2, carboplatin (AUC 6.0), and etoposide
50 mg alternating with 100 mg orally daily for 10 days. The
response rate was 47%, with seven complete responses and a
median survival of 13 months. Although these results appear supe-
rior to any previously reported, as well as to our own, the differ-
ence may at least partly be due to patient selection. Ninety per cent
of their patients had a performance status of 0 or 1 compared with
48% ofours, and 58% oftheir patients compared with 45% ofours
had only one or two sites ofmetastatic disease. The additional cost
of the paclitaxel for a palliative regimen might also be an impor-
tant consideration in some centres; furthermore, the number of
patients who received cytokines to maintain dose intensity was not
stated.
In conclusion, the combination of carboplatin with prolonged
oral etoposide has moderate activity similar to that of other plat-
inum-based regimens and is well tolerated. Because it offers the
convenience ofonly one briefoutpatient visit every 4 weeks, it is a
very reasonable choice for treatment of CUPS patients who are
candidates for palliative chemotherapy. Dosing according to esti-
mated creatinine clearance to achieve a carboplatin AUC of
6.0 mg ml-' min is recommended. Given the wide biological and
clinical heterogeneity of CUPS, it is very unlikely that an ideal
chemotherapeutic regimen will be found. Research efforts should
be directed towards obtaining a more precise pathological diag-
nosis using newer techniques, such as genetic markers, so that the
most effective tumour-specific therapy can be administered.
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